Centene Plunges to $6.6B Loss on Massive Goodwill Impairment

Ticker: CNC · Form: 10-Q · Filed: 2025-10-29T00:00:00.000Z

Sentiment: bearish

Topics: Healthcare, Managed Care, Goodwill Impairment, Net Loss, Earnings Miss, Medical Costs, 10-Q Analysis

TL;DR

Centene just took a massive $6.7 billion goodwill hit, making this quarter a total disaster; stay away until they clarify their path to recovery.

AI Summary

Centene Corporation reported a significant net loss of $6.631 billion for the three months ended September 30, 2025, a stark contrast to the net earnings of $713 million in the prior-year period. This substantial loss was primarily driven by a goodwill impairment of $6.723 billion. Total revenues increased to $49.690 billion for the quarter, up from $42.023 billion in Q3 2024, largely due to a rise in premium revenues from $36.115 billion to $44.126 billion. Medical costs also surged to $40.902 billion from $32.201 billion, reflecting increased healthcare utilization. Diluted earnings per share plummeted to a loss of $13.50, compared to earnings of $1.36 in Q3 2024. Despite the net loss, the company's cash and cash equivalents increased to $17.058 billion from $14.063 billion at December 31, 2024. The balance sheet shows total assets decreased slightly to $82.087 billion from $82.445 billion, while total liabilities rose to $61.032 billion from $55.935 billion, mainly due to an increase in medical claims liability to $21.493 billion.

Why It Matters

This filing reveals a critical financial setback for Centene, with a $6.723 billion goodwill impairment signaling potential overvaluation of past acquisitions or a deteriorating outlook for certain business segments. For investors, this translates to a significant loss of $13.50 per share, impacting shareholder value and raising questions about future profitability and strategic direction. Employees might face uncertainty if the impairment leads to restructuring or divestitures. Customers could see changes in service offerings or network providers as the company re-evaluates its portfolio. In the broader market, this could signal challenges within the managed care industry, especially for companies heavily reliant on government contracts, and may affect competitive dynamics as Centene potentially scales back or refocuses.

Risk Assessment

Risk Level: high — The goodwill impairment of $6.723 billion for the three months ended September 30, 2025, is a significant red flag, indicating a substantial write-down of asset values and directly contributing to the $6.631 billion net loss. This, coupled with a 27% increase in medical costs to $40.902 billion year-over-year, suggests underlying operational challenges and potential difficulties in managing healthcare expenses, elevating the overall risk profile.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to CNC given the massive goodwill impairment and net loss. Await further clarity from management on the specific segments affected by the impairment and their strategy to restore profitability and manage rising medical costs before considering any new positions.

Financial Highlights

debt To Equity
2.90
revenue
$49.690B
operating Margin
N/A
total Assets
$82.087B
total Debt
$17.583B
net Income
-$6.631B
eps
-$13.50
gross Margin
N/A
cash Position
$17.058B
revenue Growth
+18.2%

Revenue Breakdown

SegmentRevenueGrowth
Premium Revenues$44.126B+22.1%
Service Revenues$772M-1.5%

Key Numbers

Key Players & Entities

FAQ

Why did Centene Corporation report a net loss for the quarter ended September 30, 2025?

Centene Corporation reported a net loss of $6.631 billion for the three months ended September 30, 2025, primarily due to a significant goodwill impairment charge of $6.723 billion. This impairment was a major factor in the shift from net earnings of $713 million in the prior-year period.

How did Centene's revenues change in the third quarter of 2025?

Centene's total revenues increased to $49.690 billion for the three months ended September 30, 2025, up from $42.023 billion in the same period of 2024. This growth was largely driven by an increase in premium revenues, which rose from $36.115 billion to $44.126 billion.

What was the impact of medical costs on Centene's financial performance?

Medical costs significantly impacted Centene's financial performance, increasing to $40.902 billion for the three months ended September 30, 2025, compared to $32.201 billion in the prior-year quarter. This substantial rise in medical expenses contributed to the overall operating loss.

What was Centene's diluted earnings per share for Q3 2025?

Centene's diluted earnings per share for the three months ended September 30, 2025, was a loss of $13.50. This represents a significant decline from the diluted earnings per share of $1.36 reported for the same period in 2024.

How did Centene's cash position evolve during the nine months ended September 30, 2025?

Centene's cash and cash equivalents increased to $17.058 billion as of September 30, 2025, from $14.063 billion at December 31, 2024. This indicates a healthy liquidity position despite the reported net loss.

What is goodwill impairment and why is it significant for Centene?

Goodwill impairment occurs when the carrying value of goodwill on a company's balance sheet exceeds its fair value. For Centene, the $6.723 billion goodwill impairment is significant because it indicates that the value of past acquisitions has diminished, potentially due to changes in market conditions or the performance of acquired businesses, directly leading to a substantial net loss.

What are the key risks highlighted in Centene's 10-Q filing?

The 10-Q highlights risks such as the ability to accurately predict and manage health benefits and operating expenses, rate cuts or payment reductions from government payors, changes in federal or state laws like the ACA, and competition. The recent goodwill impairment underscores the risk of business transactions and asset valuations.

How does Centene's medical claims liability compare to the previous period?

Centene's medical claims liability increased to $21.493 billion as of September 30, 2025, from $18.308 billion at December 31, 2024. This rise suggests an increase in outstanding claims that the company expects to pay, reflecting higher medical costs.

What is Centene's outlook on future performance given the Q3 2025 results?

While the filing does not provide a direct forward-looking statement on the immediate outlook, the significant goodwill impairment and net loss suggest a challenging period. The company's cautionary statement emphasizes that actual results may differ materially from projections due to various factors, including economic, regulatory, and competitive conditions.

What non-GAAP adjustments did Centene make in its financial reporting?

Centene made several non-GAAP adjustments, including excluding amortization of acquired intangible assets ($170 million for Q3 2025), acquisition and divestiture related expenses, and other adjustments like the $6.723 billion goodwill impairment. These adjustments aim to provide a clearer view of the company's core operational performance.

Risk Factors

Industry Context

Centene operates in the highly competitive managed care industry, with a significant focus on government-sponsored healthcare programs like Medicare and Medicaid. The industry is characterized by evolving regulatory landscapes, increasing healthcare utilization, and pressure on reimbursement rates. Competitors include other large managed care organizations and smaller regional players.

Regulatory Implications

Centene's reliance on government programs makes it susceptible to changes in healthcare policy and regulations at federal and state levels. Potential shifts in reimbursement models, eligibility criteria, or program funding could significantly impact its financial performance and operational strategies.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Goodwill
An intangible asset that represents the excess of the purchase price of an acquired company over the fair value of its identifiable net assets. It reflects factors like brand reputation, customer loyalty, and synergies. (A significant goodwill impairment of $6.723 billion was recorded, directly causing the large net loss for the quarter.)
Medical Claims Liability
The amount of money a health insurer estimates it will have to pay for healthcare services that have been rendered but not yet paid. (This liability increased to $21.493 billion, indicating higher anticipated future payouts for medical services.)
Premium Revenues
Revenue generated from the fees paid by individuals or employers for health insurance coverage. (This is the primary revenue stream for Centene, and it saw a substantial increase in the quarter.)
Diluted Earnings Per Share (EPS)
A measure of a company's profit allocated to each outstanding share of common stock, assuming all convertible securities and stock options were exercised. (Plummeted to a loss of $13.50 per share, reflecting the significant net loss.)
Impairment
A charge taken when the carrying value of an asset on the balance sheet is determined to be higher than its recoverable amount, indicating a permanent reduction in value. (The $6.743 billion impairment charge (including goodwill) was the primary driver of the net loss.)

Year-Over-Year Comparison

Compared to the prior-year period (Q3 2024), Centene Corporation experienced a dramatic shift from net earnings of $713 million to a net loss of $6.631 billion, primarily driven by a $6.723 billion goodwill impairment. Total revenues saw a healthy increase of 18.2% to $49.690 billion, fueled by higher premium revenues. However, medical costs also surged by 26.9%, outpacing revenue growth and exacerbating the impact of the impairment. Diluted EPS fell sharply from $1.36 to a loss of $13.50. While cash reserves grew, total liabilities also increased, and goodwill on the balance sheet significantly decreased due to the impairment.

Filing Stats: 4,748 words · 19 min read · ~16 pages · Grade level 18.4 · Accepted 2025-10-28 19:59:02

Key Financial Figures

Filing Documents

Financial Statements

Item 1. Financial Statements 1 Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 1 Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 2 Consolidated Statements of Comprehensive Earnings (Loss) for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 3 Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 4 Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (unaudited) 6 Notes to the Consolidated Financial Statements (unaudited) 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 21

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 39

Controls and Procedures

Item 4. Controls and Procedures 39 Part II Other Information

Legal Proceedings

Item 1. Legal Proceedings 40

Risk Factors

Item 1A. Risk Factors 40

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 41

Other Information

Item 5. Other Information 41

Exhibits

Item 6. Exhibits 42

Signatures

Signatures 43 Table of Contents CAUTIONARY STATEMENT ON FORWARD-LOOKING STATEMENTS All statements, other than statements of current or historical fact, contained in this filing are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as "believe," "anticipate," "plan," "expect," "estimate," "predict," "intend," "seek," "target," "goal," "potential," "may," "will," "would," "could," "should," "can," "continue," and other similar words or expressions (and the negative thereof). Centene Corporation and its subsidiaries (Centene, the Company, our or we) intends such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about our expected future operating or financial performance, changes in laws and regulations, market opportunity, expectations concerning pricing actions, competition, expected contract start dates and terms, expected activities in connection with completed and future acquisitions and dispositions, our investments, and the adequacy of our available cash resources. These statements may be found in the various sections of this filing, such as Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations," Part II, Item 1. "Legal Proceedings," and Part II, Item 1A. "Risk Factors." These forward-looking statements reflect our current views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions, business strategies, operating environments, future developments, and other factors we believe appropriate. By their nature, forward-looking statements involve know

Financial Statements

Item 1. Financial Statements. CENTENE CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In millions, except shares in thousands and per share data in dollars) September 30, 2025 December 31, 2024 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 17,058 $ 14,063 Premium and trade receivables 23,109 19,713 Short-term investments 2,179 2,622 Other current assets 1,716 1,601 Total current assets 44,062 37,999 Long-term investments 18,180 17,429 Restricted deposits 1,416 1,390 Property, software and equipment, net 2,161 2,067 Goodwill 10,835 17,558 Intangible assets, net 4,840 5,409 Other long-term assets 593 593 Total assets $ 82,087 $ 82,445 LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY Current liabilities: Medical claims liability $ 21,493 $ 18,308 Accounts payable and accrued expenses 16,875 13,174 Return of premium payable 1,568 2,008 Unearned revenue 656 661 Current portion of long-term debt 38 110 Total current liabilities 40,630 34,261 Long-term debt 17,545 18,423 Deferred tax liability 810 684 Other long-term liabilities 2,047 2,567 Total liabilities 61,032 55,935 Commitments and contingencies Redeemable noncontrolling interests 23 10 Stockholders' equity: Preferred stock, $ 0.001 par value; authorized 10,000 shares; no shares issued or outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value; authorized 800,000 shares; 623,120 issued and 491,414 outstanding at September 30, 2025, and 620,195 issued and 495,907 outstanding at December 31, 2024 1 1 Additional paid-in capital 20,713 20,562 Accumulated other comprehensive (loss) ( 100 ) ( 504 ) Retained earnings 9,775 15,348 Treasury stock, at cost ( 131,706 and 124,288 shares, respectively) ( 9,441 ) ( 8,997 ) Total Centene stockholders' equity 20,948 26,410 Nonredeemable noncontrolling interest 84 90 Total stockholders' equity 21,032 26,500 Total liabilities, redeemable noncontroll

View on Read The Filing